相关实验视频

Updated: Sep 12, 2025

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

印第戈天然用于炎症性肠病:来自动物研究和分子机制的证据

Jie Hu¹, Mengen Zhou¹, Li Huang¹

¹Department of Anorectal Surgery, Shanghai Municipal Hospital of Traditional Chinese Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Frontiers in pharmacology

|August 4, 2025

概括

在临床前模型中,天然 (IN) 显著改善了炎症性肠病 (IBD). 高剂量的IN在减少炎症和促进恢复方面表现最有前途.

科学领域:

药理学药理学是指药理学的学科.
胃肠病学胃肠病学
免疫学免疫学免疫学

背景情况:

天然 (IN) 是一种传统的中医药,用于炎症性肠病 (IBD),特别是性结肠炎 (UC).
从临床前试验中关于IN对IBD有效性的定量证据是有限的.

研究的目的:

在IBD的动物模型中进行元分析,评估Indigo naturalis (IN) 的治疗效果.
在临床前IBD研究中提供基于证据的量化评估IN的疗效.

主要方法:

搜索了多个数据库 (PubMed,科学网络,Embase等) 对于相关的动物研究.
通过使用CAMARADES10点检查清单进行文献选和偏见风险评估.
进行了分析,重点关注组织病理指数作为主要结果指标.

主要成果:

包括15项符合条件的研究;超过一半的研究具有偏差风险低.
治疗显著改善了组织病理指数 (SMD = -2.69,p < 0.00001).
高剂量IN (>600 mg/kg) 是最有效的;IN降低了疾病活性,改善了体重恢复,并调节了炎症标志物 (IL-1β,IL-6,TNF-α,IL-10).

结论:

天然 (IN) 在临床前IBD模型中显示出显著的治疗效果.
超过600mg/kg的剂量在减少炎症方面特别有效.
IN保护结肠粘膜,并通过多个分子途径发挥有益作用,包括免疫调节和肠道微生物群的改变.

关键词:

克罗恩氏病是什么克罗恩氏病是什么他的病理学指数.印第戈天然植物 (indigo naturalis) 是一种天然的植物.炎症性肠病是一种炎症性肠病.性结肠炎是一种

更多相关视频

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...